Aralez Pharmaceuticals Inc. (TSE:ARZ), a biopharma stock, announced that it will acquire the U.S. rights to Toprol-XL from AstraZeneca
Sean Mason | October 4, 2016 | SmallCapPower
An AstraZeneca drug buy lifted a biopharma stock Tuesday. Here’s some small stocks making big moves on Tuesday, October 4, 2016 (as of 4 pm EST):
Biopharma stock Aralez Pharmaceuticals Inc. (TSE:ARZ) gained 7% to $7.03 on Tuesday after announcing that it will acquire the U.S. rights to Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca. Toprol-XL is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long term treatment of angina pectoris and treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins.
As well, shares of Sirios (CVE:SOI) sank 28% to $0.65 as the gold explorer released the first results of the ongoing diamond drilling campaign at its flagship Cheechoo gold project in Quebec, which included grades of 11.2 g/t gold over 5.8 metres including 56.2 g/t gold over 1.1 metres.
dynaCERT Inc. (CVE:DYA) stock, meanwhile, continued to move higher Tuesday, up to 25% to $0.37. Shares of the carbon emission reduction technology provider have soared 160% since the Company reported last Thursday that certain major shareholders including directors of the company have entered into a formal strategic Voluntary Lock-Up Agreement for a total of more than 55 million shares for a term of 180 days.
Finally, Zecotek Photonics Inc. (CVE:ZMS) shares rose 4% to $0.28 after the developer of photonics technologies for industrial, healthcare and scientific markets announced that total unaudited revenue for fiscal 2016 increased 235% to a record $1,513,712.
Ubika Research/SmallCapPower has received compensation to provide analyst research coverage. For full disclosure please visit here >>.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.